Therapeutic Product Immunogenicity Community

 View Only


To provide a forum for academic, industry, and regulatory colleagues to engage, align and communicate more effectively on immunogenicity topics related to drug development. The scope is modality agnostic and pertains to immunogenicity risk identification and mitigation through proactively understanding relevance and immunogenicity data interpretation in the context of non clinical and clinical studies, data reporting and harmonization outputs and terminology.

If you're not a member of this community and would like to join it, click the orange Join button,
navigate to "Communities" in your membership profile, and tick the box next to the community name.


Chair: Jochem Gokemeijer | Vice Chair: Yi Wen | Past Chair: Fiona Glassman | Secretary: Laurent Malherbe | Learning Opportunities Managers: Michele Gunsior, Shobha Purushothama, Martin Ullmann | Member Engagement Managers: Kirk Hofman

2022 Therapeutic Product Immunogenicity Goals (PDF)

Community email address: aaps-[email protected]

Latest Discussion Posts

Please login to see all eligible discussion postings.

Reach out to [email protected] if you need assistance.

Latest Shared Files

Log in to see this information

Reach out to [email protected] if you need assistance.